Takeda has concluded the previously announced acquisition of the complete shares of Nimbus Therapeutics’ tyrosine kinase 2 (TYK2) programme subsidiary Nimbus Lakshmi.
The latest move comes following clearance from the United States Federal Trade Commission and after satisfaction of other conditions related to the deal closure.
Go deeper with GlobalData
Takeda originally signed the acquisition agreement in December last year.
According to the agreement and following the deal completion, Nimbus will receive nearly $4bn in upfront payment from Takeda.
This payment will be made after adjusting items including closing account payable and closing indebtedness of Lakshmi.
Additionally, Nimbus is eligible for two milestone payments of $1bn each from Takeda after achieving $4bn in annual net sales and $5bn of products developed from the TAK-279 programme.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataTakeda global portfolio division president Ramona Sequeira said: “With our plan to acquire announced in December, we are excited to have promptly added TAK-279, a highly selective oral TYK2 inhibitor with truly transformative potential for patients in multiple diseases, to our late-stage pipeline.
“This programme closely aligns with our strategy and expertise in immune-mediated diseases, and we look forward to sharing more details of our development plans soon.”
With this transaction, Takeda has now acquired TAK-279, formerly known as NDI-034858 at Nimbus.
Phase III clinical trial of TAK-279 in psoriasis is expected to commence this year.
TAK-279 is said to have the potential to demonstrate safety, efficacy and convenience in psoriasis and other immune-mediated diseases.
These diseases include psoriatic arthritis, inflammatory bowel disease and systemic lupus erythematosus.
Takeda noted that the acquisition would boost its growing late-stage pipeline while expanding its portfolio.
